Endocrine and metabolic evaluation of classic Klinefelter syndrome and high-grade aneuploidies of sexual chromosomes with male phenotype: are they different clinical conditions? by Spaziani, Matteo et al.
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
https://doi.org/10.1530/EJE-17-0902
Endocrine and metabolic evaluation of classic 
Klinefelter syndrome and high-grade 
aneuploidies of sexual chromosomes with 
male phenotype: are they different clinical 
conditions?
Matteo Spaziani, Benedetta Mileno, Fabio Rossi, Simona Granato, Natascia Tahani, 
Antonella Anzuini, Andrea Lenzi and Antonio F Radicioni
Section of Medical Pathophysiology and Endocrinology, Department of Experimental Medicine,  
Sapienza University of Rome, Rome, Italy
Abstract
Objective: Klinefelter syndrome (KS) is the most common sex chromosome aneuploidy in males. As well as classic 
KS, less frequent higher-grade aneuploidies (HGAs) are also possible. While KS and HGAs both involve testicular 
dysgenesis with hypergonadotropic hypogonadism, they differ in many clinical features. The aim of this study was to 
investigate the endocrinal and metabolic differences between KS and HGAs.
Design: Cross-sectional, case-control study.
Methods: 88 patients with KS, 24 with an HGA and 60 healthy controls. Given the known age-related differences 
all subjects were divided by age into subgroups 1, 2 and 3. Pituitary, thyroid, gonadal and adrenal functions were 
investigated in all subjects. Metabolic aspects were only evaluated in subjects in subgroups 2 and 3.
Results: FT4 and FT3 levels were significantly higher in HGA than in KS patients in subgroups 1 and 2; in subgroup 3,  
FT4 was significantly higher in controls than in patients. Thyroglobulin was significantly higher in HGA patients in 
subgroup 1 than in KS patients and controls. Hypergonadotropic hypogonadism was confirmed in both KS and HGA 
patients, but was more precocious in the latter, as demonstrated by the earlier increase in gonadotropins and the 
decrease in testosterone, DHEA-S and inhibin B. Prolactin was significantly higher in HGA patients, starting from 
subgroup 2. Total and LDL cholesterol were significantly higher in HGA patients than in KS patients and controls, 
while HDL cholesterol was higher in controls than in patients.
Conclusions: KS and HGAs should be considered as two distinct conditions.
Introduction
Klinefelter syndrome (KS), described for the first time by 
Harry F. Klinefelter in 1942 (1), is the most common form 
of male sex chromosome aneuploidy, with an estimated 
frequency of 1:500–1:1000 in the male population (2). 
It is the consequence of a nondisjunction mechanism, 
which occurs during paternal or maternal meiosis, leading 
to the classic 47,XXY karyotype (3). In adults, it typically 
presents with tall stature, small testes, sparse body hair, 
gynaecomastia, gynoid appearance, hypergonadotropic 
hypogonadism, hyalinization and fibrosis of the 
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seminiferous tubules and, consequently, azoospermia 
(4, 5, 6, 7, 8, 9, 10). As well as the classic 47,XXY form 
of KS, higher-grade aneuploidies (HGAs) are possible: 
48,XXYY, the most common, with an incidence of 1:18 
000–1:40 000 (11); 48,XXXY, seen in about 1:50 000 males 
(12); 49,XXXXY, whose incidence is near 1:85 000–1:100 
000 (12) and 49,XXXYY, whose real incidence is currently 
unknown, with only six cases reported in the literature.
The first description of an HGA dates back to an 
article by Marco Fraccaro published in The Lancet in 
1960 (13), which described a 7-year-old child with 49 
chromosomes. These very rare conditions all involve the 
testicular dysgenesis associated with hypergonadotropic 
hypogonadism typical of KS, and for this reason, are 
usually considered as variants of KS (14), even though 
they have their own distinct aspects: dysmorphic facial 
features, skeletal deformities, hypotonic musculature, 
tremors, genital anomalies and neurologic and cognitive 
impairment (15, 16, 17, 18, 19). The aim of this study was 
to investigate, for the first time in the scientific literature, 
the endocrinal and metabolic differences between classic 
47,XXY KS and the HGAs, in order to obtain sufficient 
objective data to consider them as different conditions.
Subjects and methods
We selected 1873 hypogonadal patients and 60 healthy 
subjects from a cohort of 3230 subjects attending the Rare 
Disease Centre at Umberto I Policlinico between March 
2010 and April 2016. Of the hypogonadal patients, 699 
(58%) were newly diagnosed: of these, 267 (38.2%) were 
diagnosed with KS, while 24 (3.4%) were affected by 
HGAs. The exclusion criteria of testosterone replacement 
therapy, age >45  years and non-consent, led to the 
elimination of a further 179 KS patients, while no HGA 
patients had to be excluded (Fig. 1).
Consequently, eighty-eight 47,XXY patients (KS 
group: age 2.5–44 years; mean age ± s.d.: 23 ± 10), twenty-
four patients with higher-grade aneuploidies (HGA group: 
age 1.9–34 years; mean age ± s.d.: 17 ± 9.4) and sixty age-
matched healthy subjects (control group: age 3.5–40; 
mean age ± s.d.: 24 ± 9.7) underwent laboratory hormone 
tests. Patients in the HGA group had the following 
karyotypes: four with 48,XXXY; twelve with 48,XXYY and 
eight with 49,XXXXY.
Pituitary, thyroid, gonadal and adrenal function was 
studied by measurement of the following hormones: 
thyroid-stimulating hormone (TSH), free triiodothyronine 
(FT3), free thyroxine (FT4), thyroglobulin (Tg), follicle-
stimulating hormone (FSH), luteinizing hormone (LH), 
total testosterone (T), 17 beta-estradiol (E2), inhibin 
B (INHB), sex hormone-binding globulin (SHBG), 
prolactin (PRL), delta 4-androstenedione (Δ4) and 
dehydroepiandrosterone sulfate (DHEA-S).
As already noted, at the time of the study, none of the 
subjects were taking testosterone replacement therapy or 
other endocrine-active drugs.
Given the age-related differences in the endocrine 
system, the subjects were divided into three further 
subgroups by age: subgroup 1 (age ≤12 years: 12 KS patients 
aged 2.5–10.9  years; mean age ± s.d.: 6.6 ± 2.6; 8 HGA 
patients aged 1.9–11.8 years; mean age ± s.d.: 6.9 ± 2.8; 15 
controls aged 3.5–11.6  years; mean age ± s.d.: 7.3 ± 3.2); 
subgroup 2 (age >12 and ≤20 years: 26 KS patients aged 
12.9–19.8 years; mean age ± s.d.: 17.1 ± 1.8; 8 HGA patients 
aged 12.8–19.7  years; mean age ± s.d.: 16.7 ± 2.3; 20 
controls aged 12.1–19.9 years; mean age ± s.d.: 18 ± 2) and 
subgroup 3 (age >20 years: 50 KS patients aged 20.7–44 
years; mean age ± s.d.: 30.2 ± 6.7; 8 HGA patients aged 
20.8–34 years; mean age ± s.d.: 26.6 ± 4.4; 25 controls aged 
21.1–40 years; mean age ± s.d.: 29.9 ± 5.9). There were no 
statistically significant differences in age between the 
subgroups. Investigation of Tanner pubertal stage revealed 
the following: KS patients: 7 G1 and 5 G2 in subgroup 
Figure 1
Flow chart of the recruitment process for patients and control 
subjects attending the Rare Disease Centre at Umberto I 
Policlinico between 2010 and 2016.
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1; 8 G3, 12 G4 and 6 G5 in subgroup 2; all G5 in subgroup 
3. HGA patients: 5 G1 and 3 G2 in subgroup 1; 1 G2, 3 G3 
and 4 G4 in subgroup 2 and, as with the KS patients, all 
G5 in subgroup 3.
Subjects in subgroups 2 and 3 also underwent an 
evaluation of lipid and glucose metabolism, with the 
analysis of total, LDL and HDL cholesterol, triglycerides, 
basal blood glucose, 2-h glucose (after OGTT), basal 
insulin, 2-h insulin (after OGTT), HOMA index and 
glycated haemoglobin.
Hormone assay
Baseline blood samples were obtained from all subjects 
by antecubital venous puncture in the early morning 
(07:30–09:00 h) after an overnight fast. Samples were 
centrifuged after 30′ and the serum was immediately 
frozen at −20°C.
TSH, FT3, FT4, FSH, LH, SHBG, PRL, DHEA-S, E2 and 
T were measured in duplicate with chemiluminescent 
microparticle immunoassay (CMIA, Architect System; 
Abbott Laboratories) with limits of detection (LOD) of 
≤0.0025 μIU/mL, ≤1.0 pg/mL, ≤0.4 ng/dL, 0.05 IU/mL, 
0.07 IU/mL, ≤0.1 nmol/L, 0.25 ng/mL, ≤3.0 μg/dL, 
≤10 pg/mL and 0.28 nmol/L respectively. Intra- and inter-
assay coefficients of variation for our laboratory were: 
3.6 and 5.4% at 2.71 μIU/mL (TSH); 2.8 and 5.2% at 
2.76 pg/mL (FT3); 3.1 and 5.1% at 1.07 ng/dL (FT4); 3.6% 
and 5.4% at 3.2 IU/mL (FSH); 3.8 and 5.5% at 4.1 IU/mL 
(LH); 5.65% and 9.54% at 8.8 nmol/L (SHBG); 3.32% and 
6.92% at 4.19 ng/mL (PRL); 2.68% and 7.41% at 10.7 μg/
dL (DHEA-S); 5% and 7% at 190 and 600 pg/mL (E2) 2.1% 
and 3.6% at 10.08 nmol/L (T). Serum Tg was measured 
by chemiluminescent assay (ACCESS; Beckman Coulter 
Laboratories, Brea, CA,USA) with a LOD of 0.1 ng/mL 
and intra- and inter-assay coefficient of variation <10% 
at >1 ng/mL (20, 21). Serum concentrations of INHB 
were measured by enzyme-linked immunosorbent assay 
(ELISA) (GEN II, Beckman Coulter laboratories) with LOD 
of 7.0 pg/mL, while intra- and inter-assay coefficients of 
variation were 3.3% and 7.2% at 122 pg/mL. Finally ∆4 
was measured with radioimmunoassay (RIA) (Cisbio 
Bioassays, Codolet, France) with LOD 5 ng/dL; intra- and 
inter- assay coefficients of variation were 7.4% and 8.1% 
at 168 ng/dL.
The reference ranges for pre-pubertal subjects were 
0.87–5.19 μIU/mL for TSH; 3.09–5.59 pg/mL for FT3; 
1.01–1.60 ng/dL for FT4; <0.05–2.00 IU/mL for FSH; 
<0.07–1.80 IU/mL for LH; <0.28–2.2 nmol/L for T; 
16.50–242.80 μg/dL for DHEA-S. Normal ranges for 
pubertal adolescents were 0.76–4.51 μIU/mL for TSH; 
2.77–5.51 pg/mL for FT3; 0.85–1.48 ng/dL for FT4. Finally, 
the reference ranges for adulthood were 0.49–3.87 μIU/mL 
for TSH; 2.32–4.31 pg/mL for FT3; 0.81–1.34 ng/dL for 
FT4; 1.15–45.00 ng/mL for Tg; 1.38–9.58 IU/mL for 
FSH; 1.79–8.17 IU/mL for LH; 10.40–38.20 nmol/L 
for T; 24–108 pg/mL for E2; 80–380 pg/mL for INHB; 
11.1–78.2 nmol/L for SHBG; 2.63–13.14 ng/mL for PRL; 
130–286 ng/dL for ∆4; 133.1–592.00 μg/dL for DHEA-S.
Total cholesterol, HDL cholesterol and triglycerides 
were measured by an enzymatic colorimetric assay 
(respectively Roeschlau, 1974 – Sugiuchi, 1995 – Siedel, 
1993), while LDL cholesterol was calculated according 
to Friedwald’s equation. Glucose was measured by the 
hexochinase-G6PD method (UV-Kunst, 1984), while 
insulin was determined by an electrochemiluminescent 
assay (Clark, 1999). Glycated haemoglobin was assessed 
by high-performance liquid chromatography.
This study was approved by the Institutional Ethics 
Committee.
Statistical analysis
Data are expressed as mean ± s.d. or median and 95% 
confidence interval. To enable the statistical analysis, 
when INHB, FSH, LH and T were below the LOD, the 
value of respectively 4 pg/mL, 0.03 IU/mL, 0.04 IU/mL 
and 0.20 nmol/L were used arbitrarily. Comparisons 
between two groups were carried out by Student T test 
for parametric analysis and the Mann–Whitney U test for 
non-parametric data. Comparisons among three groups 
were performed through ANOVA variance analysis, while 
the differences in medians, for non-parametric analysis, 
were calculated using the Kruskal–Wallis test. Statistical 
significance is given as a 95% confidence interval 
(P < 0.05).
Results
All results are reported as mean ± s.d. unless otherwise 
indicated.
Pituitary-testis axis and DHEA-S
Subgroup 1
Blood serum concentrations of FSH and DHEA-S were 
significantly higher in HGA than in KS patients (FSH: 
1.5 ± 0.83 vs 0.37 ± 0.14 IU/mL; P < 0.005; DHEA-S: 44 ± 11 
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vs 25 ± 20 µg/dL; P < 0.05) and FSH was higher in HGA 
patients than controls (1.5 ± 0.83 vs 0.71 ± 0.44 IU/mL; 
P < 0.005) (Figs 2 and 3).
Subgroup 2
There were significant differences in LH and FSH between 
KS patients and controls (LH: 11 ± 5.6 vs 3.2 ± 1.0 IU/mL; 
P < 0.0001; FSH: 24 ± 12 vs 3.5 ± 1.9 IU/mL; P < 0.0001), 
between HGA patients and controls (LH: 15 ± 4.6 vs 
3.2 ± 1.0 IU/mL; P < 0.0001; FSH: 35 ± 10 vs 3.5 ± 1.9 IU/mL; 
P < 0.0001) and between KS and HGA patients (LH: 11 ± 5.6 
vs 15 ± 4.6 IU/mL; P < 0.05; FSH: 24 ± 12 vs 35 ± 10 IU/mL; 
P < 0.05) (Fig. 2). It is clear that gonadotropin levels were 
higher in HGA than in KS patients, and both had higher 
concentrations than seen in age-matched controls.
The following results and significance levels were 
observed for T; HGA vs controls: 8.5 ± 4.0 vs 20 ± 6.1 nmol/L; 
P < 0.0001; KS vs controls: 15 ± 4.5 vs 20 ± 6.1 nmol/L; 
P < 0.005; HGA vs KS: 8.5 ± 4.0 vs 15 ± 4.5 nmol/L; P < 0.05 
(Fig.  4). For INHB the results were as follows: HGA vs 
controls: 5.3 ± 1.5 vs 162 ± 67 pg/mL; P < 0.0001; KS vs 
controls: 18 ± 15 vs 162 ± 67 pg/mL; P < 0.0001; HGA vs 
KS: 5.3 ± 1.5 vs 18 ± 15 pg/mL; P < 0.05 (Fig. 4).
There was a significant difference in levels of the 
adrenal hormone DHEA-S between KS and HGA patients 
(203 ± 112 vs 124 ± 67 µg/dL; P < 0.05), between KS 
patients and controls (203 ± 112 vs 387 ± 120 µg/dL; 
P < 0.05) and between HGA patients and controls 
(124 ± 67 vs 387 ± 120 µg/dL; P < 0.01) (Fig. 3). For SHBG 
and PRL (Figs 3 and 4), significant differences were seen 
between HGA patients and controls (SHBG: 48 ± 21 vs 
31 ± 13 nmol/L; P < 0.05; PRL: 22 ± 12 vs 7.3 ± 2.0 ng/mL; 
P < 0.005), while there was a significant difference 
Figure 2
Box plots of gonadotropins in patients and control subgroups. 
Median, minimum and maximum values (whiskers) are 
reported for subgroups 1, 2 and 3. Mean (+) and ANOVA P 
values are also reported: (A, B and D) FSH plasma levels. 
°°°P < 0.005 vs KS and ***P < 0.005 vs controls; °P < 0.05 vs KS; 
****P < 0.0001 vs controls. (C and E) LH plasma levels. 
****P < 0.0001 vs controls; °P < 0.05 vs KS.
Figure 3
Box plots of DHEA-S and SHBG in patients and control 
subgroups. Median, minimum and maximum values (whiskers) 
are reported for subgroups 1, 2 and 3. Mean (+) and ANOVA P 
values are also reported: (A, B and C) DHEA-S plasma levels. 
*P < 0.05 vs controls; **P < 0.01 vs controls; °P < 0.05 vs KS. (D 
and E) SHBG plasma levels. ***P < 0.001 vs controls; *P < 0.05 
vs controls.
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between KS and HGA patients in PRL alone (10 ± 5.0 vs 
22 ± 12 ng/mL; P < 0.05).
Subgroup 3
There was a significant difference in FSH and LH levels 
between KS patients and controls (FSH: 30 ± 14 vs 
3.5 ± 1.9 IU/mL; P < 0.0001; LH: 15 ± 5.6 vs 3.2 ± 1.0 IU/
mL; P < 0.0001) and between HGA patients and controls 
(FSH: 31 ± 13 vs 3.5 ± 1.9 IU/mL; P < 0.0001; LH: 17 ± 7.7 
vs 3.2 ± 1.0 IU/mL; P < 0.0001) (Fig.  2). DHEA-S, T and 
INHB (Figs  3 and 4) were higher in controls than in 
KS patients (DHEA-S: 387 ± 120 vs 288 ± 150 µg/dL; 
P < 0.05; T: 20 ± 6.1 vs 14 ± 6.5 nmol/L; P < 0.005; INHB: 
162 ± 67 vs 5.5 ± 3.1 pg/mL; P < 0.0001) and HGA 
patients (DHEA-S: 387 ± 120 vs 254 ± 41 µg/dL; P < 0.05; 
T: 20 ± 6.1 vs 13 ± 4.7 nmol/L; P < 0.0001; INHB: 162 ± 67 
vs 5.6 ± 1.1 pg/mL; P < 0.0001). SHBG levels were higher 
in KS patients than controls (43 ± 17 vs 31 ± 13 nmol/L; 
P < 0.001) (Fig.  3). Finally, there was a significant 
difference in PRL between KS patients and controls 
(11 ± 4.9 vs 7.3 ± 2.0 ng/mL; P < 0.05), between KS and 
HGA patients (11 ± 4.9 vs 46 ± 32 ng/mL; P < 0.05) 
and between HGA patients and controls (46 ± 32 vs 
7.3 ± 2.0 ng/mL; P < 0.0001).
There were no significant differences in E2 and Δ4 
between controls and patients in any of the subgroups 
(Table 1).
Pituitary-thyroid axis
Before describing the results, it must be stressed that 
all thyroid hormone levels in all subjects (KS, HGA and 
controls) fell within the normal range.
Subgroup 1
There was a significant difference between KS and HGA 
patients in FT4 (1.0 ± 0.08 vs 1.2 ± 0.14 ng/dL; P < 0.05) and 
Tg (12 ± 6.5 vs 26 ± 4.9 ng/mL; P < 0.05). There was also a 
significant difference between HGA patients and controls 
in Tg (26 ± 4.9 vs 14 ± 6.2 ng/mL; P < 0.005) (Table 1).
Subgroup 2
FT3 levels were significantly higher in HGA than KS 
patients (3.7 ± 0.32 vs 3.3 ± 0.26 pg/mL; P < 0.05) (Table 1).
Subgroup 3
There were significant differences in FT4 between KS 
patients and controls (1.0 ± 0.15 vs 1.13 ± 0.10 ng/
dL; P < 0.005) and between HGA patients and controls 
(0.95 ± 0.09 vs 1.13 ± 0.10 ng/dL; P < 0.0005) (Table 1).
Lipid profile
As already noted, the lipid profile investigation involved 
the analysis of total cholesterol, LDL cholesterol, HDL 
cholesterol and triglycerides in subgroups 2 and 3 
(Table 2).
Subgroup 2
Total and LDL cholesterol were significantly higher in HGA 
than in KS patients (total: 160 ± 6.7 vs 141 ± 18 mg/dL; 
Figure 4
Box plots of testosterone, inhibin B and prolactin in patients 
and control subgroups. Median, minimum and maximum 
values (whiskers) are reported for subgroups 1, 2 and 3. Mean 
(+) and ANOVA P values are also reported: (A and B) 
Testosterone plasma levels. ****P < 0.0001 vs controls; 
**P < 0.005 vs controls; °P < 0.05 vs KS. (C and D) Inhibin B 
plasma levels. ****P < 0.0001 vs controls; °P < 0.05 vs KS. (E and 
F) Prolactin plasma levels. ****P < 0.0001 vs controls; 
**P < 0.005 vs controls; *P < 0.05 vs controls; °P < 0.05 vs KS.
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P < 0.05; LDL: mean ± s.d.: 99 ± 6.9 vs 75 ± 17 mg/dL; 
P < 0.005) and controls (total: 160 ± 6.7 vs 128 ± 26 mg/
dL; P < 0.05; LDL: 99 ± 6.9 vs 47 ± 11 mg/dL; P < 0.0005). 
LDL cholesterol was significantly higher in KS patients 
than in controls (75 ± 17 vs 47 ± 11 mg/dL; P < 0.0005). 
In contrast, HDL cholesterol concentrations were higher 
in controls than in KS and HGA patients (controls vs KS: 
74 ± 22 vs 54 ± 13 mg/dL; P < 0.01; controls vs HGA: 74 ± 22 
vs 43 ± 5.8 mg/dL; P < 0.005). There were no significant 
differences in triglycerides in this subgroup (Table 2).
Subgroup 3
The results in this subgroup are generally similar to those 
for subgroup 2. Total cholesterol was significantly higher 
in KS and HGA patients than controls (KS vs controls: 
181 ± 30 vs 126 ± 18 mg/dL; P < 0.0001; HGA vs controls: 
211 ± 49 vs 126 ± 18 mg/dL; P < 0.0001). The results for LDL 
cholesterol reflect those for subgroup 2 (KS vs controls: 
107 ± 28 vs 45 ± 13 mg/dL; P < 0.0001; HGA vs controls: 
147 ± 46 vs 45 ± 13 mg/dL; P < 0.0001). LDL concentrations 
were also higher in HGA than in KS patients (147 ± 46 vs 
107 ± 28 mg/dL; P < 0.05). Finally, HDL cholesterol was 
higher in controls than in KS and HGA patients (controls 
vs KS: 64 ± 17 vs 52 ± 17 mg/dL; P < 0.05; controls vs HGA: 
64 ± 17 vs 46 ± 6.5 mg/dL; P < 0.05). Here too, there were 
no significant differences in triglycerides (Table 2).
Glucose profile
Evaluation of glucose profile included OGTT, insulin, 
HOMA index and glycated haemoglobin. No statistically 
significant differences were seen between KS patients, 
HGA patients and controls. Although higher values for 
these parameters were seen in HGA than KS patients in 
subgroup 2, this trend was almost completely reversed in 
subgroup 3 (Table 2).
Discussion
To our knowledge, the present study is the first to evaluate 
endocrinal and metabolic features in HGA patients and 
the differences between such patients and patients with 
classic 47,XXY KS. It is also the first to perform a triple 
comparison among classic KS, HGA and control subjects.
Table 1 Thyroid hormone profile, 17 beta-estradiol and delta 4-androstenedione (Δ4) mean values in patients and control 
groups. Data are reported as mean ± s.d.
KS HGA Controls
Subgroup 1 (age ≤12)
 n 12 8 15
 TSH (µIU/mL) 2.1 ± 1.1 2.5 ± 1.4 2.4 ± 1.4
 FT3 (pg/mL) 3.7 ± 0.36 3.8 ± 0.41 4.0 ± 0.50
 FT4 (ng/dL) 1.0 ± 0.08 1.2 ± 0.14a 1.1 ± 0.12
 Tg (ng/mL) 12 ± 6.5 26 ± 4.9a,b 14 ± 6.2
 E2 (pg/mL) 15.6 ± 8.5 11 ± 2.7 10.5 ± 1.2
 Δ4 (ng/dL) 25.8 ± 21.9 34 ± 6.1 38.6 ± 28.5
Subgroup 2 (12 < age ≤ 20)
 n 26 8 20
 TSH (µIU/mL) 1.6 ± 0.97 1.5 ± 0.92 2.1 ± 0.34
 FT3 (pg/mL) 3.3 ± 0.26 3.7 ± 0.32a 3.6 ± 0.53
 FT4 (ng/dL) 0.98 ± 0.14 1.1 ± 0.06 1.1 ± 0.10
 Tg (ng/mL) 13 ± 9.8 16 ± 10 8.2 ± 3.7
 E2 (pg/mL) 25 ± 10.2 21 ± 10.2 25.5 ± 8.8
 Δ4 (ng/dL) 204.9 ± 84.2 176 ± 88.9 195 ± 8.8
Subgroup 3 (age >20)
 n 50 8 25
 TSH (µIU/mL) 1.5 ± 0.79 1.6 ± 0.30 1.52 ± 0.69
 FT3 (pg/mL) 3.1 ± 0.35 3.0 ± 0.28 3.11 ± 0.29
 FT4 (ng/dL) 1.0 ± 0.15b 0.95 ± 0.09c 1.13 ± 0.10
 Tg (ng/mL) 19 ± 22 24 ± 26 8.77 ± 6.13
 E2 (pg/mL) 34 ± 19.4 26 ± 7.8 30.2 ± 14.7
 Δ4 (ng/dL) 223.1 ± 109.9 177 ± 53 182.4 ± 46.5
aP < 0.05 vs KS, bP < 0.005 and cP < 0.0005 vs controls.
Controls, healthy subjects; HGA, high-grade aneuplodies’ patients; KS, Klinefelter syndrome’s patients.
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
178:4 349Clinical Study M Spaziani and others 47,XXY syndrome and high-
grade aneuploidies
www.eje-online.org
The testicles are the glands most affected by these 
conditions and our hormone data confirmed, in 
both classic KS patients and in those with HGAs, the 
presence of hypergonadotropic hypogonadism, caused 
by primary testicular damage, as demonstrated by the 
severe hypotrophy and the very low INHB blood levels. 
In KS patients aged ≤12 years, gonadotropin values were 
comparable to those of control subjects, while HGA 
patients showed an initial increase in FSH, with a mean 
value of 1.5 IU/mL; this was significantly higher than that 
in KS patients, seeming to indicate an earlier testicular 
damage.
The expected increase in gonadotropins during late 
pre-puberty and adolescence (12–20-year subgroup) was 
seen in both patient populations, with significantly higher 
values than in the controls (FSH concentrations greater 
than LH on average). In the same age group, HGA patients 
had significantly greater values of gonadotropins, while 
in patients over 20 years, these subjects still had higher 
levels of FSH and LH than KS patients, but the difference 
was no longer statistically significant.
There was no difference in total testosterone between 
KS patients, HGA patients and controls in subjects aged 
≤12  years. In contrast, in the 12- to 20-year subgroup, 
HGA patients showed T levels below the normal reference 
range, and significantly lower than in KS patients 
and controls. In the oldest subgroup (>20  years), the 
difference in total T (generally in the lower part of the 
normal reference range) between KS and HGA patients 
was not statistically significant, but in both groups, it was 
significantly lower than observed in the control subjects.
As expected, INHB values were similar in all subjects 
in the youngest subgroup. During late pre-puberty and 
the first phase of testicular development, there was a 
dramatic drop in INHB, which was more rapid and severe 
in the HGAs. In the 12–20 subgroup, KS patients showed 
significantly higher levels of INHB than HGA patients, in 
whom the levels were frankly pathological (mean 18 pg/
mL vs 5.3 pg/mL), but this difference had disappeared in 
the oldest subgroup, in which INHB in both KS and HGA 
patients was significantly lower than in controls.
Evaluation of adrenal gland function by DHEA-S 
gave contrasting results. In the youngest subgroup, HGA 
patients had significantly higher DHEA-S values (similar 
to controls) than KS children, while the opposite was seen 
in the 12–20 subgroup. In the oldest subgroup, similar 
DHEA-S concentrations were seen in both KS and HGA 
patients; these were in the lower part of the normal 
Table 2 Lipid profile, OGTT, HOMA index and glycated haemoglobin values in patients and control groups. Data are reported as 
mean ± s.d. or median and lower and upper CI 95%.
KS HGA Controls
Subgroup 2 (12 < age ≤ 20)
 n 26 8 20
 Total cholesterol (mg/dL) 141 ± 18 160 ± 6.7a,b 128 ± 26
 LDL (mg/dL) 75 ± 17f 99 ± 6.9e,f 47 ± 11
 HDL (mg/dL) 54 ± 13c 43 ± 5.8d 74 ± 22
 Triglycerides (mg/dL) 66; 58–87 90; 50–114 60; 49–83
 Basal glucose (mg/dL) 82; 78–84 90; 58–110 83; 79–87
 2-h glucose (mg/dL) 87; 78–94 94; 89–101 90; 76–108
 Basal insulin (µU/mL) 6.2; 4.9–8.2 10; 5.3–11.2 6.7; 5.0–8.9
 2-h insulin (µU/mL) 15; 9.9–34 44; 31.1–48 9.9; 7.1–18
 HOMA index 1.3; 0.96–1.8 2.1; 1.5–2.3 1.5; 1.1–2.2
 Glycated haemoglobin (%) 5.0; 4.8–5.3 5.3; 1.5–9.1 4.9; 4.6–5.2
Subgroup 3 (age >20)
 n 50 8 25
 Total cholesterol (mg/dL) 181 ± 30g 211 ± 49g 126 ± 18
 LDL (mg/dL) 107 ± 28g 147 ± 46a,g 45 ± 13
 HDL (mg/dL) 52 ± 17b 46 ± 6.5b 64 ± 17
 Tryglicerides (mg/dL) 86; 76–122 78; 45–132 76; 67–92
 Basal glucose (mg/dL) 86; 84–91 91; 81–97 95; 88–113
 2-h glucose (mg/dL) 93; 87–100 90; 74–97 96; 83–114
 Basal insulin (µU/mL) 4.2; 3.5–14 9.4; 3.9–13 5.6; 5.7–11
 2-h insulin (µU/mL) 10; 5.1–35 7.0; 0.5–12 6.9; 6.5–11
 HOMA index 0.9; 0.53–3.1 2.2; 0.91–2.7 1.3; 1.2–2.4
 Glycated haemoglobin (%) 5.2; 4.9–5.6 5.0; 4.7–5.3 5.2; 4.9–5.6
aP < 0.05 vs KS; bP < 0.05 vs controls; cP < 0.01 vs controls; dP < 0.005 vs controls; eP < 0.005 vs KS; fP < 0.0005 vs controls; gP < 0.0001 vs controls.
Controls, healthy subjects; HGA, high-grade aneuplodies’ patients; KS, Klinefelter syndrome’s patients.
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reference range, but significantly lower than those in 
control subjects.
SHBG levels dropped over time in all subjects. In the 
12- to 20-year subgroup, HGA patients had significantly 
higher levels (albeit within the normal range) than KS 
patients and controls. In the oldest subgroup, both KS and 
HGA patients showed similar concentrations that were 
higher than in the controls, but this was only statistically 
significant in the KS group, probably due to the smaller 
number of HGA subjects.
The evolution of gonadotropin, T and INHB levels 
indicated early testicular damage in HGA patients. However, 
levels of these hormones in KS and HGA patients become 
similar in adulthood. We hypothesize that the influence 
of the greater genetic weight of the supernumerary X 
and Y chromosomes could be responsible for this early 
testicular failure, but further studies are necessary to 
better understand the real underlying genetic mechanism.
In our daily clinical practice, a drop in DHEA-S is 
one of the first signs of late-onset hypogonadism, and 
is often a precursor to declining T levels (22). DHEA-S as 
well as T and INHB, showed a premature decline in HGA 
in comparison with KS patients but, in contrast with our 
clinical observations of normal karyotype male subjects, 
its level began dropping concomitantly with testosterone, 
not earlier.
PRL levels in the youngest age group were normal. In 
the 12- to 20-year subgroup, PRL was significantly higher 
in HGA patients than in KS patients and controls, who 
had similar values. This rise was even more evident in the 
oldest subgroup, with double the concentration of the 12- 
to 20-year subgroup. This hormone was pathologically 
high in 23% and 24% of KS patients in subgroups 2 and 
3 and in 62% and 64% of HGA patients in subgroup 2 
and 3. This might be explained by hyperactivation of the 
stress axis, related to the various physical and cognitive 
difficulties, which affect these patients.
Study of the hypothalamic-pituitary-thyroid axis 
demonstrated normal secretion of TSH, FT3 and FT4 in KS 
and HGA patients in all age subgroups. However, higher 
FT4 in the youngest subgroup and higher FT3 in the 12–20 
subgroup were seen in HGA than KS, whereas in the oldest 
group, the controls had significantly higher FT4 levels, as 
also demonstrated by Bjørn and coll. (23).
It should also be noted that in the 12–20 subgroup, 
KS patients had lower FT3 levels than the controls; this 
difference was not statistically significant (Table  1), 
probably due to the low number of KS patients. 
Nevertheless, it confirmed the trend seen in a previous 
study conducted by our group (24) involving a greater 
number (40 vs 26) of KS patients in Tanner stage G2-G5. 
In that case, the higher caseload enabled us to reach 
statistical significance.
In the present study, Tg values in HGA patients in the 
youngest age group were significantly higher than those 
in both KS patients and controls. In the same subgroup 
of HGA patients, we also found increased FT4 levels. 
We hypothesize that thyroid function, like prolactin 
concentration, is strongly influenced by the stress induced 
by this condition, which is characterized by more severe 
relational and clinical problems. Furthermore, some 
studies (25) have established an association between 
serum Tg values and iodine intake in the iodine-deficient 
population and suggested that Tg could serve as a sensitive 
biomarker of iodine deficiency; thus, inadequate iodine 
intake might also explain the higher Tg levels in our 
population of younger HGA subjects. Finally, there could 
be an association between higher Tg levels and decreased 
thyroid parenchymal integrity. In this study, as well as in 
our group’s previously cited paper (24), we did not find 
any differences in thyroid autoantibodies between KS and 
control subjects or between HGA and control subjects 
(data not shown).
We also studied the lipid profile in terms of total, LDL 
and HDL cholesterol and triglycerides. Total cholesterol 
was above the 75th percentile of values for controls in 
73% of KS and 55% of HGA patients; HDL was below the 
25th percentile of values for controls in 47% of KS and 
78% of HGA patients and LDL cholesterol was above the 
75th percentile of values for controls in 55% of KS and 
all HGA patients. Finally, triglyceride concentration was 
above the 75th percentile of values for controls in 36% of 
KS and 33% of HGA patients.
Total cholesterol was pathologically high in 3% of KS 
and 10% of HGA patients, and LDL was pathologically 
high in 4% and 17% respectively. In contrast, HDL was 
above the normal reference range in 56% of Klinefelter 
patients and 67% of HGA patients. Pathological 
triglyceride concentrations were found in just 3% of KS 
and no HGA patients.
The statistical analysis revealed significantly higher 
levels of total and LDL cholesterol in HGA than KS patients, 
increasing over time. Both had greater concentrations 
than controls. In contrast, HDL cholesterol was on 
average higher in KS than HGA patients, although this 
difference was not statistically significant. No differences 
in triglyceride levels were seen. Our data are in agreement 
with much of the literature evidence, that describes 
increased total and LDL cholesterol and triglycerides and 
lower levels of HDL cholesterol in KS patients (26, 27, 28).
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A number of studies have identified an association 
between KS and diabetes (29). Despite this, the statistical 
analysis of our data revealed a slightly increased mean 
HOMA index in HGA patients in comparison with KS 
patients, but these values were within normal limits (score 
<2.5, insulin-resistance cut-off value) (30). Furthermore, 
impaired fasting glucose was found in just 3 KS patients 
and no HGA patients.
In conclusion, the hormonal and metabolic data 
presented in this paper definitively highlight the 
significant differences between classic KS and HGAs in 
males. In addition, and supporting our observations, 
the literature stresses the major clinical, neurologic and 
cognitive diversities that account for the greater social and 
clinical care needed by HGA patients (15, 16, 17, 18, 19).
For all these reasons, KS and HGAs of the sexual 
chromosomes (chromosomes 48 and 49) should be 
considered as two distinct medical conditions.
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